Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label, Single-arm Study of NT 201 in Patients With Chronic Sialorrhea
jRCT2051210082Completed
- Sponsor
- Teijin Pharma
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of botulinum toxin type A in hypersalivation (2 arms), sponsored by Teijin Pharma. Primary endpoint: Change in uSFR from baseline to 4 weeks post-treatment in Group A. Started Nov 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
hypersalivation
Beyond the preview
Go deeper on jRCT2051210082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210082.